Clinical Trials on Overactive Detrusor

Total 2057 results

University Of Perugia
Allergan

Completed

Onabotulinumtoxina Intradetrusorial Injections and NGF Expression (Onab/A-NGF)

Overactive Detrusor | Detrusor Hyperreflexia of Bladder

Italy
NHS Greater Glasgow and Clyde
Glasgow Caledonian University; University of Glasgow

Unknown

TPTNS: Home vs Hospital Treatment for Overactive Bladder

Overactive Bladder | Detrusor, Overactive

United Kingdom
Mayo Clinic

Completed

Botulin-A Toxin Instillations and Overactive Bladder

Overactive Bladder | Detrusor Instability | Detrusor Hyperreflexia

United States
Ankara Yildirim Beyazıt University

Completed

Comparison of Different Treatments for Overactive Bladder Syndrome

Overactive Bladder | Overactive Detrusor | Overactive Bladder Syndrome

Turkey
Teesside University
South Tees Hospitals NHS Foundation Trust

Not yet recruiting

Developing a Simple Test to Diagnose Overactive Bladder

Overactive Bladder | Overactive Bladder Syndrome | Detrusor Overactivity
Chang Gung Memorial Hospital

Unknown

Effect of beta3-adrenoceptor Agonist on Patients With Overactive Bladder and as a Urinary Biomarker

Overactive Bladder Syndrome | Detrusor Overactivity
Women and Infants Hospital of Rhode Island

Unknown

Oral vs Intravesical Analgesia for Office Bladder Botox Injections (OPIL)

Urinary Incontinence | Urge Incontinence | Overactive Bladder Syndrome | Detrusor Instability | Detrusor Hyperreflexia

United States
Assaf-Harofeh Medical Center

Completed

Plantarflexion Reduces Urgency and Peak Detrusor Pressure in Patients With Detrusor Overactivity (DO)

Overactive Detrusor

Israel
Mr HD Flood

Unknown

Botulinum Toxin in the Treatment of Idiopathic Detrusor Overactivity

Overactive Detrusor

Ireland
Assaf-Harofeh Medical Center

Completed

"Swallow my Urine Back" : Inhibition of Detrusor Overactivity by Swallowing Maneuver

Overactive Detrusor
Bayer

Completed

A Study To Assess If 10 mg Vardenafil (BAY38-9456) Taken Twice Daily For 6 Weeks Has An Effect On Bladder Function

Overactive Bladder | Detrusor Overactivity

Spain, Belgium, Canada, Netherlands, Switzerland, Russian Federation, Germany, Israel, Hungary, Portugal, France, Poland, Czech Republic
Astellas Pharma Inc

Completed

Study of 2 Doses of Solifenacin Succinate in Female Subjects With Overactive Bladder. (SHRINK)

Overactive Bladder | Detrusor Overactivity

Belgium, Norway, Spain, Sweden, Italy, Czech Republic, Hungary, France, Canada, Germany, Austria, United Kingdom, Bulgaria, Russian Federation, United States, Poland, Slovakia, Turkey, Israel, Romania
Astellas Pharma Inc

Completed

Single Dose Study to Measure Blood Levels and Safety of a Drug for Children With Overactive Bladder

Overactive Bladder | Neurogenic Detrusor Overactivity

Belgium, Canada, Denmark, Netherlands, Poland, Turkey, United Kingdom
Astellas Pharma Europe B.V.

Completed

A Study to Evaluate the Pharmacokinetics, Safety and Tolerability of Mirabegron Oral Suspension in Pediatric Subjects From 3 to Less Than 12 Years of Age With Neurogenic Detrusor Overactivity (NDO) or Overactive Bladder (OAB)

Overactive Bladder | Neurogenic Detrusor Overactivity

Denmark, Poland
Pfizer

Completed

Study Of Fesoterodine In Pediatric Overactive Bladder Patients Aged 8-17 Years

Overactive Bladder | Neurogenic Detrusor Overactivity

United States
Janssen-Cilag Ltd.,Thailand

Terminated

Extended-Release Oxybutynin for the Treatment of Neurogenic Detrusor Overactivity (RONDO)

Detrusor Function, Overactive

Thailand
Astellas Pharma Inc
Astellas Pharma Europe B.V.

Completed

A Study to Evaluate the Pharmacokinetics, Safety and Tolerability of Mirabegron OCAS (Oral Controlled Absorption System) in Pediatric Subjects With Neurogenic Detrusor Overactivity or Overactive Bladder

Overactive Bladder | Pharmacokinetics of Mirabegron | Neurogenic Detrusor Overactivity

Belgium, Denmark, Norway, Poland, Serbia
Duke University

Recruiting

Yoga for Treatment of Overactive Bladder in Pediatric Patients

Overactive Bladder | Overactive Detrusor | Overactive Bladder Syndrome

United States
The Cleveland Clinic

Terminated

Sensitivity of Extended Cultures in Diagnosing Urinary Tract Infections

Overactive Bladder | Overactive Detrusor | UTI | Urgency-Frequency Syndrome

United States
APOGEPHA Arzneimittel GmbH

Completed

Efficacy and Tolerability of Propiverine Hydrochloride in Patients With Neurogenic Detrusor Overactivity

Urologic Diseases | Urinary Incontinence | Urinary Bladder, Neurogenic | Neurogenic Urinary Bladder Disorder | Bladder Disorder, Neurogenic | Urinary Bladder Disorder, Neurogenic | Neurogenic Bladder Disorder | Urinary Bladder Neurogenic Dysfunction | Overactive Detrusor Function

Romania, Austria, Germany
Ege University

Not yet recruiting

Transcutaneous Tibial Nerve Stimulation for Idiopathic Overactive Bladder

Overactive Bladder | Overactive Detrusor | Overactive Bladder Syndrome

Turkey
Instituto Médico Tecnológico SL
University Ramon Llull

Completed

Effects of Transcutaneous and Percutaneous PTNS on Idiopathic OAB

Overactive Bladder | Overactive Detrusor | Urge Incontinence

Spain
Swiss Paraplegic Centre Nottwil

Completed

Efficacy of Two Onabotulinum Toxin Doses

Overactive Detrusor | Neurogenic Bladder

Switzerland
National Taiwan University Hospital

Completed

BO and DO in Women With Cystocele Before and After Cystocele Repair

Detrusor, Overactive | Bladder Oversensitivity

Taiwan
Università degli Studi dell'Insubria

Completed

Ultrasonographic Bladder Wall Thickness and Different Forms of Detrusor Overactivity

Detrusor Overactivity

Italy
Pfizer

Completed

BIOEQUIVALENCE STUDY IN HEALTHY PARTICIPANTS COMPARING 4 MG AND 8 MG FESOTERODINE EXTENDED-RELEASE TABLETS (TOVIAZ™), MANUFACTURED AT ZWICKAU VERSUS FREIBURG

Neurogenic Detrusor Overactivity

Belgium
Astellas Pharma Europe B.V.

Completed

Open-label Phase 3 Study With Mirabegron in Children From 3 to Less Than 18 Years of Age With Neurogenic Detrusor Overactivity (Crocodile)

Neurogenic Detrusor Overactivity

Belgium, Croatia, Turkey, Australia, Denmark, Israel, Jordan, Korea, Republic of, Latvia, Lithuania, Malaysia, Mexico, Norway, Philippines, Poland, Romania, Serbia, Slovakia, Taiwan
Taiho Pharmaceutical Co., Ltd.

Completed

Exploratory Study of TAC-302 in Detrusor Underactivity Patients With Overactive Bladder.

Overactive Bladder | Detrusor Underactivity

Japan
University of L'Aquila

Completed

Safety And Efficacy Of Solifenacin In Men With Overactive Bladder (OAB) And Detrusor Underactivity

Overactive Bladder | Detrusor Underactivity

Italy
Michael E. Chua
St. Luke's Medical Center, Philippines

Completed

Efficacy and Safety of Gabapentin in Treating Overactive Bladder (OAB)

Quality of Life | Nocturia | Incontinence | Urinary Urgency | Urinary Frequency | Detrusor Uninhibited Activity

Philippines
Astellas Pharma Europe B.V.

Completed

A Clinical Study to Investigate How Solifenacin Fluid is Taken up, How Long it Stays in the Body and How Effective and Safe it is in Treating Children Aged From 6 Months to Less Than 5 Years With Symptoms of Neurogenic Detrusor Overactivity (NDO)

Pediatric | Neurogenic Detrusor Overactivity

United States, Belgium, Korea, Republic of, Philippines, Poland, United Kingdom
Astellas Pharma Europe B.V.

Completed

A Study to Assess the Long Term Effect, Safety and Metabolism of a Solifenacin Liquid Suspension in Participants 5 to 18 Years of Age With Neurogenic Detrusor Overactivity

Neurogenic Detrusor Overactivity

United States, Belgium, Brazil, Denmark, Hungary, Korea, Republic of, Mexico, Philippines, Poland, Turkey
MedtronicNeuro

Terminated

Efficacy Study of Pudendal Neuromodulation for the Treatment of Neurogenic Overactive Bladder (ACCEPTANCE)

Urinary Incontinence | Detrusor Overactivity | Neurogenic Overactive Bladder

Belgium, France, United Kingdom, Germany, Italy, Netherlands
Pierre and Marie Curie University

Completed

Reproductibility of Cystometry in Multiple Sclerosis Patient

Multiple Sclerosis | Overactive Bladder | Lower Urinary Tract Symptoms | Overactive Detrusor | Cystometry

France
Northwell Health
Medtronics, Inc.

Completed

UNGF Assessment in Patients With Detrusor Overactivity Undergoing Sacral Neuromodulation

Detrusor Overactivity

United States
KYU-SUNG LEE
Samsung Medical Center

Completed

Prognostic Value of the Urinary Nerve Growth Factor in the Patients With Benign Prostatic Hyperplasia

Overactive Detrusor | Benign Prostatic Hypertrophy With Outflow Obstruction

Korea, Republic of
Buddhist Tzu Chi General Hospital

Completed

Injections of Botulinum Toxin A in Treatment of Patients With Detrusor Overactivity and Impaired Contractility

Botulinum Toxins, Type A

Taiwan
Boston Urogynecology Associates

Completed

Minimizing Pain During Office Intradetrussor Botox Injection

Overactive Bladder | Overactive Detrusor | Urge Incontinence | Overactive Bladder Syndrome | Overactivity; Behavior

United States
AbbVie

Completed

Safety and Efficacy Evaluation of Oxybutynin Topical Gel In Children With Neurogenic Bladder

Overactive Detrusor | Neurogenic Bladder

United States
Bayer

Terminated

Study of Darifenacin in Patients Suffering From Multiple Sclerosis and Neurogenic Detrusor Overactivity

Multiple Sclerosis | Overactive Detrusor

Germany
The Cleveland Clinic

Enrolling by invitation

Migraine Medication Effects on Urinary Symptoms

Overactive Bladder | Migraine | Migraine Disorders | Overactive Detrusor | Interstitial Cystitis | Overactive Bladder Syndrome | Bladder Pain Syndrome

United States
Pfizer

Completed

Study To Assess The Bioequivalence Under Fed And Fasted Conditions Of The Fesoterodine Beads-In-Capsule SR4 And SR7 Formulations And To Estimate The Bioavailability of SR7 Beads Sprinkled On Apple Sauce Relative To The Beads-In-Capsule SR7 Formulation Administer

Neurogenic Detrusor Overactivity

Belgium
The Methodist Hospital Research Institute
Collaborating for the Advancement of Interdisciplinary Research in Benign...

Recruiting

Optimization of OnabotulinumtoxinA (BTX-A) Injection for the Treatment of Neurogenic Lower Urinary Tract Dysfunction (BOND)

Overactive Bladder | Lower Urinary Tract Symptoms | Neurogenic Bladder | Neurogenic Detrusor Overactivity | Neuro: Neurogenic Bladder

United States
Pfizer

Completed

Open-label Long-term Extension Study of Fesoterodine in Japanese Subjects With Neurogenic Detrusor Overactivity.

Urinary Bladder, Neurogenic

Japan
Sunnybrook Health Sciences Centre
ethica Clinical Research Inc.

Completed

Intravesical Injection of Botulinum Toxin A Versus Saline for Neurogenic Detrusor Overactivity

Neurogenic Detrusor Overactivity

Canada
Astellas Pharma Global Development, Inc.

Recruiting

A Study of Mirabegron in Young Children With Neurogenic Detrusor Overactivity

Neurogenic Detrusor Overactivity

Philippines, Turkey, Belgium, Denmark
Warner Chilcott

Terminated

A Two-week Open-label Pharmacodynamic and Pharmacokinetic Study of Multiple Doses of a Darifenacin Liquid Oral Suspension in Children (2 - 15 Years) With Neurogenic Detrusor Overactivity

Neurogenic Detrusor Overactivity

United States, Colombia
Mayo Clinic

Terminated

Over Active Bladder Instillation Study - Botox

Overactive Bladder | Urinary Incontinence | Urge Incontinence | Urinary Urge Incontinence | Detrusor Hyperreflexia

United States
Chang Gung Memorial Hospital

Completed

Extracoporeal Shock Wave Therapy (ESWT) for the Treatment of Detrusor Underactivity/ Underactive Bladder (DU/UAB)

Detrusor Underactivity | Detrusor, Underactive

Taiwan
RECORDATI GROUP

Completed

Effects of Rec 0/0438 in Patients With Neurogenic Detrusor Overactivity Due to Spinal Cord Injury

Neurogenic Detrusor Overactivity

Czechia, France, Poland, Portugal

Clinical Trials on Overactive Detrusor

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Mali

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations